---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-002474"
form_type: "8-K"
ticker: null
cik: "0001792581"
company_name: "Kiromic Biopharma, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:03:51.563472+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Kiromic BioPharma issues $1M 25% secured convertible note to existing holder

## Summary
- Note principal $1,000,000, 25% interest p.a., matures Jan 28, 2026.
- Convertible at 90% of 5-day VWAP starting Feb 28, 2025, subject to 19.99% beneficial ownership limit.
- Secured by all company fixtures, equipment, and intellectual property.
- Same holder now holds $13.2M aggregate principal across 8 notes plus preferred stock.
- Issued under Section 4(a)(2) exemption; prepayable without penalty on 10 days' notice.

## SEC filing metadata
- accession: 0001437749-25-002474
- form_type: 8-K
- cik: 0001792581
- company_name: Kiromic Biopharma, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792581/000143774925002474/0001437749-25-002474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792581/000143774925002474/krbp20250202_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-002474
- JSON: https://secwatch.observer/filing/0001437749-25-002474.json
- Plain text: https://secwatch.observer/filing/0001437749-25-002474.txt

## Key facts
- Debt Financings
  Kiromic Biopharma, Inc. incurred convertible notes of $1,000,000 with an accredited investor at 25% per annum maturing January 28, 2026.
  - Instrument: convertible notes
  - Principal: $1,000,000
  - Counterparty: an accredited investor
  - Rate: 25% per annum
  - Maturity: January 28, 2026
  - Event: incurrence
  source text: BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor (the “Holder”). The Note has a principal amount of $1,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on January 28, 2026 (the “Maturity Date”), on which the principal balance and accrued but unpaid interest
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792581/000143774925002474/0001437749-25-002474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.